2023 World Conference on Lung Cancer (Posters)-EP05.01. Propective Study: Usefulness of D-Dimer Determination for Thromboembolic Disease Screening in Patients with Metastatic Lung Cancer.

EP05.01. Propective Study: Usefulness of D-Dimer Determination for Thromboembolic Disease Screening in Patients with Metastatic Lung Cancer. - PDF(Abstract)

Back to course

Pdf Summary

This prospective study evaluated the usefulness of determining D-Dimer levels for screening thromboembolic disease (TE) in patients with metastatic lung cancer. D-Dimer is a fibrin degradation product that indicates fibrinolysis after thrombosis, and elevated levels are commonly seen in TE and neoplasms. The study included 45 patients with stage IV lung cancer, with 22% having small cell lung cancer (SCLC) and 78% having non-small cell lung cancer (NSCLC). The patients underwent clinical history, physical examination, and chest CT, and D-Dimer values were determined at baseline. <br /><br />The study used a cut-off point of 500 ng/ml for D-Dimer values, where higher values may indicate TE and lower values may rule out the diagnosis. The results showed that 93% of the patients had elevated D-Dimer levels, with a range of 222-19877 ng/ml, but none of them had TE. This suggests that in patients with both SCLC and NSCLC, D-Dimer determination is not a useful tool for screening TE.<br /><br />In summary, this study found that D-Dimer levels were elevated in a high percentage of patients with metastatic lung cancer, but it did not correlate with the presence of TE. Therefore, D-Dimer determination may not be an effective screening test for thromboembolic disease in this patient population.

Asset Subtitle

Teresa García Manrique

Meta Tag

Speaker Teresa García Manrique

Topic Pulmonology & Staging

Keywords

prospective study

D-Dimer levels

screening

thromboembolic disease

metastatic lung cancer

fibrin degradation product

fibrinolysis

neoplasms

small cell lung cancer

non-small cell lung cancer